Laboratoires Pierre Fabre SA - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 41 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Laboratoires Pierre Fabre SA - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Laboratoires Pierre Fabre SA - Product Pipeline Review - 2014', provides an overview of the Laboratoires Pierre Fabre SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Laboratoires Pierre Fabre SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Laboratoires Pierre Fabre SA including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Laboratoires Pierre Fabre SA's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Laboratoires Pierre Fabre SA's pipeline products

Reasons to buy

- Evaluate Laboratoires Pierre Fabre SA's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Laboratoires Pierre Fabre SA in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Laboratoires Pierre Fabre SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Laboratoires Pierre Fabre SA and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Laboratoires Pierre Fabre SA
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Laboratoires Pierre Fabre SA and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Laboratoires Pierre Fabre SA Snapshot 5
Laboratoires Pierre Fabre SA Overview 5
Key Information 5
Key Facts 5
Laboratoires Pierre Fabre SA - Research and Development Overview 6
Key Therapeutic Areas 6
Laboratoires Pierre Fabre SA - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Out-Licensed Products 11
Out-Licensed Products/Combination Treatment Modalities 12
Laboratoires Pierre Fabre SA - Pipeline Products Glance 13
Laboratoires Pierre Fabre SA - Late Stage Pipeline Products 13
Phase III Products/Combination Treatment Modalities 13
Laboratoires Pierre Fabre SA - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
Laboratoires Pierre Fabre SA - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Laboratoires Pierre Fabre SA - Drug Profiles 17
ibuprofen 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
J022-X ST 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
vinflunine ditartrate 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
F-373280 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
levomilnacipran ER 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
mequitazine 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
propranolol hydrochloride 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
V-0251 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
F-98203 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Laboratoires Pierre Fabre SA - Pipeline Analysis 28
Laboratoires Pierre Fabre SA - Pipeline Products by Target 28
Laboratoires Pierre Fabre SA - Pipeline Products by Route of Administration 30
Laboratoires Pierre Fabre SA - Pipeline Products by Molecule Type 31
Laboratoires Pierre Fabre SA - Pipeline Products by Mechanism of Action 32
Laboratoires Pierre Fabre SA - Recent Pipeline Updates 34
Laboratoires Pierre Fabre SA - Dormant Projects 37
Laboratoires Pierre Fabre SA - Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41

List of Tables
Laboratoires Pierre Fabre SA, Key Information 5
Laboratoires Pierre Fabre SA, Key Facts 5
Laboratoires Pierre Fabre SA - Pipeline by Indication, 2014 8
Laboratoires Pierre Fabre SA - Pipeline by Stage of Development, 2014 9
Laboratoires Pierre Fabre SA - Monotherapy Products in Pipeline, 2014 10
Laboratoires Pierre Fabre SA - Out-Licensed Products in Pipeline, 2014 11
Laboratoires Pierre Fabre SA - Out-Licensed Products/ Combination Treatment Modalities, 2014 12
Laboratoires Pierre Fabre SA - Phase III, 2014 13
Laboratoires Pierre Fabre SA - Phase II, 2014 14
Laboratoires Pierre Fabre SA - Phase I, 2014 15
Laboratoires Pierre Fabre SA - Preclinical, 2014 16
Laboratoires Pierre Fabre SA - Pipeline by Target, 2014 29
Laboratoires Pierre Fabre SA - Pipeline by Route of Administration, 2014 30
Laboratoires Pierre Fabre SA - Pipeline by Molecule Type, 2014 31
Laboratoires Pierre Fabre SA - Pipeline Products by Mechanism of Action, 2014 33
Laboratoires Pierre Fabre SA - Recent Pipeline Updates, 2014 34
Laboratoires Pierre Fabre SA - Dormant Developmental Projects,2014 37
Laboratoires Pierre Fabre SA, Other Locations 38
Laboratoires Pierre Fabre SA, Subsidiaries 39